That’s the key idea put forth in preliminary research posted this month to bioRxiv, authored by GSC, UBC and BC Children's Hospital Research Institute scientists, that highlights the potential benefits of testing COVID-19 patients for genetic variants of ACE2—the protein identified as the point-of-entry for the SARS-COV-2 virus into human cells.
